secwatch.observer — SEC 8-K summary
======================================

Issuer:     DiaMedica Therapeutics Inc. (DMAC)
CIK:        0001401040
Form:       8-K
Filed at:   2025-11-12T23:59:59+00:00
Accession:  0001437749-25-034467
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

DiaMedica Q3 net loss $8.6M; ReMEDy2 trial at 50% enrollment
------------------------------------------------------------

- Net loss $8.6M in Q3 2025, up from $6.3M a year ago; R&D expense $6.4M, up from $5.0M.
- Cash and short-term investments $55.3M as of Sept 30, 2025; funded into 2H 2027.
- ReMEDy2 Phase 2/3 AIS trial enrollment nearing 50% of 200-patient interim target.
- Preeclampsia IST Part 1a expansion cohort enrolling; Part 3 fetal growth restriction screening starting soon.
- Pre-IND meeting with FDA on DM199 for preeclampsia held; update after minutes received.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1401040/000143774925034467/0001437749-25-034467-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1401040/000143774925034467/dmtp20251112_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-034467

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer